Last reviewed · How we verify
NCT03679559
Exercise in Improving Health and Quality of Life in Breast Cancer Survivors
NA trial testing Best Practice in Invasive Breast Carcinoma in 83 participants. Completed in 2 June 2022.
2 June 2022
Quick facts
| Lead sponsor | Roswell Park Cancer Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 83 |
| Start date | 6 October 2017 |
| Primary completion | 2 June 2022 |
| Estimated completion | 2 June 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Best Practice
- Exercise Intervention (home walking program and resistance training)
- Exercise Intervention (home-based Zumba program and resistance training)
- Exercise Intervention (HIIT program and resistance training)
- Informational Intervention
- Laboratory Biomarker Analysis — full drug profile →
- Monitoring Device
- Quality-of-Life Assessment
- Questionnaire Administration
Conditions studied
- Invasive Breast Carcinoma — all drugs for Invasive Breast Carcinoma →
Sponsor
Roswell Park Cancer Institute
Who can join
Eligibility, any sex, with Invasive Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized pilot trial studies how well exercise works in improving health and quality of life in breast cancer survivors. Participating in an exercise program to maintain physical activity may help to improve health and quality of life in breast cancer survivors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Physical Activity as an Imperative Support in Breast Cancer Management.
Ortega MA, Fraile-Martínez O, García-Montero C, Pekarek L, et al · · 2020 · cited 34× · PMID 33379177 · DOI 10.3390/cancers13010055
Verify or expand the search:
- PubMed search for NCT03679559
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Best Practice
Trials testing the same drug.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
- NCT05874297 — Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer · NA · not yet recruiting
- NCT07176000 — Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington S · NA · not yet recruiting
Other recruiting trials for Invasive Breast Carcinoma
Currently open trials in the same condition.
- NCT07137416 — Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for H · Phase 1 · recruiting
- NCT06763328 — Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy · Phase 3 · recruiting
- NCT05406232 — Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer · recruiting
- NCT05710328 — Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRE · Phase 2 · active not recruiting
- NCT05023967 — Metformin and Nightly Fasting in Women With Early Breast Cancer · Phase 2 · active not recruiting
Other Roswell Park Cancer Institute trials
Trials by the same sponsor.
- NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
- NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
- NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
- NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03679559 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
- Last refreshed: 1 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03679559.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing